Literature DB >> 7153317

Inactivation of Lassa, Marburg, and Ebola viruses by gamma irradiation.

L H Elliott, J B McCormick, K M Johnson.   

Abstract

Because of the cumbersome conditions experienced in a maximum containment laboratory, methods for inactivating highly pathogenic viruses were investigated. The infectivity of Lassa, Marburg, and Ebola viruses was inactivated without altering the immunological activity after radiation with Co60 gamma rays. At 4 degrees C, Lassa virus was the most difficult to inactivate with a rate of 5.3 X 10(-6) log 50% tissue culture infective dose per rad of CO60 radiation, as compared with 6.8 X 10(-6) log 50% tissue culture infective dose per rad for Ebola virus and 8.4 X 10(-6) log 50% tissue culture infective dose per rad for Marburg virus. Experimental inactivation curves, as well as curves giving the total radiation needed to inactivate a given concentration of any of the three viruses, are presented. We found this method of inactivation to be superior to UV light or beta-propiolactone inactivation and now routinely use it for preparation of material for protein-chemistry studies or for preparation of immunological reagents.

Entities:  

Mesh:

Year:  1982        PMID: 7153317      PMCID: PMC272450          DOI: 10.1128/jcm.16.4.704-708.1982

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  12 in total

1.  Photochemical inactivation of DNA and RNA viruses by psoralen derivatives.

Authors:  C V Hanson; J L Riggs; E H Lennette
Journal:  J Gen Virol       Date:  1978-08       Impact factor: 3.891

Review 2.  Arenavirus taxonomy: a review.

Authors:  F A Murphy
Journal:  Bull World Health Organ       Date:  1975       Impact factor: 9.408

3.  [On the etiology of an unknown human infection originating from monkeys].

Authors:  R Siegert; H L Shu; W Slenczka; D Peters; G Müller
Journal:  Dtsch Med Wochenschr       Date:  1967-12-22       Impact factor: 0.628

4.  Arenaviruses.

Authors:  C J Pfau; G H Bergold; J Casals; K M Johnson; F A Murphy; I R Pedersen; W E Rawls; W P Rowe; P A Webb; M C Weissenbacher
Journal:  Intervirology       Date:  1974       Impact factor: 1.763

5.  Indirect immunofluorescence for the diagnosis of Lassa fever infection.

Authors:  H Wulff; J V Lange
Journal:  Bull World Health Organ       Date:  1975       Impact factor: 9.408

6.  Isolation and partial characterisation of a new virus causing acute haemorrhagic fever in Zaire.

Authors:  K M Johnson; J V Lange; P A Webb; F A Murphy
Journal:  Lancet       Date:  1977-03-12       Impact factor: 79.321

7.  Preparation and use of erythrocyte-globulin conjugates to Lassa virus in reversed passive hemagglutination and inhibition.

Authors:  R A Goldwasser; L H Elliott; K M Johnson
Journal:  J Clin Microbiol       Date:  1980-06       Impact factor: 5.948

8.  Virion nucleic acid of Ebola virus.

Authors:  R L Regnery; K M Johnson; M P Kiley
Journal:  J Virol       Date:  1980-11       Impact factor: 5.103

9.  Lassa fever, a new virus disease of man from West Africa. 3. Isolation and characterization of the virus.

Authors:  S M Buckley; J Casals
Journal:  Am J Trop Med Hyg       Date:  1970-07       Impact factor: 2.345

10.  Effects of actinomycin D and ultraviolet and ionizing radiation on Pichinde virus.

Authors:  M F Carter; F A Murphy; J P Brunschwig; C Noonan; W E Rawls
Journal:  J Virol       Date:  1973-07       Impact factor: 5.103

View more
  55 in total

1.  Gamma irradiated blood samples: unsuitability for haemostatic evaluation of high risk patients.

Authors:  D Cummins; T Southee; K Walshe; I J Mackie; S J Machin
Journal:  J Clin Pathol       Date:  1989-06       Impact factor: 3.411

Review 2.  Laboratory Diagnosis of Lassa Fever.

Authors:  Vanessa Raabe; Jeffrey Koehler
Journal:  J Clin Microbiol       Date:  2017-04-12       Impact factor: 5.948

3.  Change in blood test after irradiation with high doses for inactivation of Lassa virus.

Authors:  K Eberlein; G Hintereder; S Schilling; C Rödel; L Jüling-Pohlit
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-08-26       Impact factor: 3.267

4.  Buffer AVL Alone Does Not Inactivate Ebola Virus in a Representative Clinical Sample Type.

Authors:  Sophie J Smither; Simon A Weller; Amanda Phelps; Lin Eastaugh; Sarah Ngugi; Lyn M O'Brien; Jackie Steward; Steve G Lonsdale; Mark S Lever
Journal:  J Clin Microbiol       Date:  2015-07-15       Impact factor: 5.948

5.  Effect of two virus inactivation methods: electron beam irradiation and binary ethylenimine treatment on determination of reproductive hormones in equine plasma.

Authors:  N C Kyvsgaard; R Høier; I Brück; P Nansen
Journal:  Acta Vet Scand       Date:  1997       Impact factor: 1.695

6.  Effect of viral decontamination measures on Wright-stained blood smears.

Authors:  Jay N Lozier; Katherine R Calvo
Journal:  Blood       Date:  2015-02-19       Impact factor: 22.113

7.  Gamma Irradiation as an Effective Method for Inactivation of Emerging Viral Pathogens.

Authors:  Friederike Feldmann; W Lesley Shupert; Elaine Haddock; Barri Twardoski; Heinz Feldmann
Journal:  Am J Trop Med Hyg       Date:  2019-05       Impact factor: 2.345

8.  Detection of Lassa virus antigens and Lassa virus-specific immunoglobulins G and M by enzyme-linked immunosorbent assay.

Authors:  B S Niklasson; P B Jahrling; C J Peters
Journal:  J Clin Microbiol       Date:  1984-08       Impact factor: 5.948

9.  Sterility of gamma-irradiated pathogens: a new mathematical formula to calculate sterilizing doses.

Authors:  Eve V Singleton; Shannon C David; Justin B Davies; Timothy R Hirst; James C Paton; Michael R Beard; Farhid Hemmatzadeh; Mohammed Alsharifi
Journal:  J Radiat Res       Date:  2020-11-16       Impact factor: 2.724

10.  Intranasal flu vaccine protective against seasonal and H5N1 avian influenza infections.

Authors:  Mohammed Alsharifi; Yoichi Furuya; Timothy R Bowden; Mario Lobigs; Aulikki Koskinen; Matthias Regner; Lee Trinidad; David B Boyle; Arno Müllbacher
Journal:  PLoS One       Date:  2009-04-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.